We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+8.06%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$1.11T
AUM Growth
+$49.3B
Cap. Flow
-$2.91B
Cap. Flow %
-0.26%
Top 10 Hldgs %
27.74%
Holding
3,121
New
186
Increased
817
Reduced
1,825
Closed
148

Top Buys

Rank Stock Value
1
RIVN icon
Rivian
RIVN
+$18.7B
2
AAPL icon
Apple
AAPL
+$5.48B
3
NVDA icon
NVIDIA
NVDA
+$5.33B
4
TSLA icon
Tesla
TSLA
+$4.47B
5
MSFT icon
Microsoft
MSFT
+$2.15B

Top Sells

Rank Stock Value
1
V icon
Visa
V
+$4.26B
2
META icon
Meta Platforms (Facebook)
META
+$3.3B
3
MS icon
Morgan Stanley
MS
+$2.82B
4
GPN icon
Global Payments
GPN
+$2.43B
5
PYPL icon
PayPal
PYPL
+$2B

Sector Composition

Rank Sector Weight
1 Technology 27.36%
2 Healthcare 16.09%
3 Consumer Discretionary 15.79%
4 Communication Services 12.38%
5 Financials 10.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BHC icon
2976
Bausch Health
BHC
$2.32B
-1,402,927
Closed -$39.1M
BVS icon
2977
Bioventus
BVS
$1.17B
-2,674,299
Closed -$37.9M
CASI
2978
DELISTED
CASI Pharmaceuticals
CASI
-8,750
Closed -$104K
CLB icon
2979
Core Laboratories
CLB
$571M
-7,500
Closed -$208K
CMCT
2980
Creative Media & Community Trust
CMCT
$13.7M
-1
Closed -$138K
CODX
2981
Co-Diagnostics
CODX
$5.45M
-1,180
Closed -$344K
COMP icon
2982
Compass
COMP
$9.77B
-27,194
Closed -$361K
CRMD icon
2983
CorMedix
CRMD
$557M
-17,527
Closed -$82K
CVM icon
2984
CEL-SCI Corp
CVM
$25.9M
-706
Closed -$233K
DHT icon
2985
DHT Holdings
DHT
$3.01B
-12,177
Closed -$80K
DWSN icon
2986
Dawson Geophysical
DWSN
$136M
-30,980
Closed -$77K
EFC
2987
Ellington Financial
EFC
$1.76B
-11,718
Closed -$214K
ELTX icon
2988
Elicio Therapeutics
ELTX
$80.4M
-1,270
Closed -$124K
EPIX
2989
DELISTED
ESSA Pharma
EPIX
-24,303
Closed -$194K
ERNA icon
2990
Eterna Therapeutics
ERNA
$5.16M
-3
Closed -$191K
ESPR
2991
DELISTED
Esperion Therapeutics
ESPR
-22,522
Closed -$271K
ETON icon
2992
Eton Pharmaceutcials
ETON
$1.14B
-24,206
Closed -$122K
FF icon
2993
Future Fuel
FF
$257M
-10,619
Closed -$76K
FMS icon
2994
Fresenius Medical Care
FMS
$12.6B
-20,758
Closed -$726K
FRO icon
2995
Frontline
FRO
$8.81B
-10,131
Closed -$95K
GRWG icon
2996
GrowGeneration
GRWG
$105M
-19,734
Closed -$487K
HLX icon
2997
Helix Energy Solutions
HLX
$1.49B
-12,018
Closed -$47K
HSTM icon
2998
HealthStream
HSTM
$829M
-7,253
Closed -$207K
HTLD icon
2999
Heartland Express
HTLD
$950M
-23,131
Closed -$371K
HY icon
3000
Hyster-Yale Materials Handling
HY
$614M
-6,847
Closed -$344K

Similar funds

T. Rowe Price Associates's Q4 2021 Portfolio in Review

As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.

T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
  • T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
  • T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
  • T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
  • T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
  • T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
  • T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.